163 related articles for article (PubMed ID: 36994675)
1. BRCAness in biliary tract cancer: a new prognostic and predictive biomarker?
Hachem S; Kassis Y; Hachem MC; Zouein J; Gharios J; Kourie HR
Biomark Med; 2023 Jan; 17(1):51-57. PubMed ID: 36994675
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
Kim H; Kim JY; Park KU
Oncology; 2023; 101(1):41-48. PubMed ID: 36257294
[TBL] [Abstract][Full Text] [Related]
4. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
Rimini M; Macarulla T; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Nappo F; Nichetti F; Lai E; Valgiusti M; Cappetta A; Febregat C; Fassan M; De Braud F; Puzzoni M; Frassineti GL; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Eur J Cancer; 2022 Aug; 171():232-241. PubMed ID: 35749808
[TBL] [Abstract][Full Text] [Related]
5. Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.
Li YC; Li KS; Liu ZL; Tang YC; Hu XQ; Li XY; Shi AD; Zhao LM; Shu LZ; Lian S; Yan ZD; Huang SH; Sheng GL; Song Y; Liu YJ; Huan F; Zhang MH; Zhang ZL
Front Immunol; 2022; 13():1049812. PubMed ID: 36389727
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
8. Revision of potential prognostic markers of cholangiocarcinoma for clinical practice.
Saengboonmee C; Obchoei S; Sawanyawisuth K; Wongkham S
Expert Rev Anticancer Ther; 2023 May; 23(5):517-530. PubMed ID: 37052887
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
12. Biliary Tract Cancer: Molecular Biology of Precursor Lesions.
Manzano-Núñez F; Prates Tiago Aguilar L; Sempoux C; Lemaigre FP
Semin Liver Dis; 2023 Nov; 43(4):472-484. PubMed ID: 37944999
[TBL] [Abstract][Full Text] [Related]
13. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Inflammation-based Prognostic Scores in Patients With Biliary Tract Cancer After Surgical Resection.
Utsumi M; Kitada K; Tokunaga N; Yoshida Y; Narusaka T; Hamano R; Miyasou H; Tsunemitsu Y; Otsuka S; Inagaki M
Anticancer Res; 2021 Apr; 41(4):2147-2155. PubMed ID: 33813426
[TBL] [Abstract][Full Text] [Related]
15. Current omics-based biomarkers for cholangiocarcinoma.
Intuyod K; Armartmuntree N; Jusakul A; Sakonsinsiri C; Thanan R; Pinlaor S
Expert Rev Mol Diagn; 2019 Nov; 19(11):997-1005. PubMed ID: 31566016
[No Abstract] [Full Text] [Related]
16. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.
Nakagawa H; Hayata Y; Yamada T; Kawamura S; Suzuki N; Koike K
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29895797
[TBL] [Abstract][Full Text] [Related]
17. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.
Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X
BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis.
Kunlabut K; Vaeteewoottacharn K; Wongkham C; Khuntikeo N; Waraasawapati S; Pairojkul C; Wongkham S
Asian Pac J Cancer Prev; 2012; 13 Suppl():95-9. PubMed ID: 23480770
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into molecular and immune subtypes of biliary tract cancers.
Bramel ER; Sia D
Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.
Boyd S; Mustonen H; Tenca A; Jokelainen K; Arola J; Färkkilä MA
Scand J Gastroenterol; 2017 Feb; 52(2):242-249. PubMed ID: 27806633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
